MeritValue

Amneal Pharmaceuticals, Inc.

AMRXdata completeness 100%10 fiscal years on file

Data notes: no data for concept 'interestExpense'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$2.09B1$2.21B2$2.39B3$2.79B3$3.02B3
Net income$13.2M4−$270.6M4−$84M5−$116.9M5$72.1M5
Operating cash flow$241.8M6$65.1M7$345.6M8$295.1M8$340M8
Capital expenditure$47.7M9$46.4M10$43.2M11$51.9M11$70.1M11
Free cash flow (derived)$194.1M6$18.7M7$302.4M8$243.2M8$269.9M8
Total debt$5.42B12$5.24B13$4.84B14$4.77B15$5.14B15
Cash & equivalents$247.8M16$26M17$91.5M18$110.6M18$282M18
Diluted shares151.8M150.9M176.1M309.0M324.8M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
You’d own
0.0000031%
of the whole company
Your share of last year’s profit
$2.22
Your share of its debt
$158.36
Your share of free cash flow
$8.31
iii. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
$12.21
assumptions (10)
  • riskFreeRate4.5%
  • equityRiskPremium5.0%
  • beta100.0%
  • equityWeight85.0%
  • costOfDebtSpread1.5%
  • taxRate21.0%
  • terminalGrowth2.5%
  • projectionYears10
  • fcfGrowth11.6%
  • fcfBase$269.9M
DCF · Growth Exit 5Y
$4.97
assumptions (10)
  • riskFreeRate4.5%
  • equityRiskPremium5.0%
  • beta100.0%
  • equityWeight85.0%
  • costOfDebtSpread1.5%
  • taxRate21.0%
  • terminalGrowth2.5%
  • projectionYears5
  • fcfGrowth11.6%
  • fcfBase$269.9M
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
book value / share count missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

iv. The price question — last, on purpose
What does today’s price assume?
Type a price. The ledger answers.
Or set your own belief
FCF growth, next 5 years11.6%
Discount rate (WACC)8.78%
Terminal growth2.5%
At your growth, a share is worth $4.97

Default growth 11.6%= this company’s own filed history (median-to-median FCF CAGR, clamped 0–20%). Your adjustments are recorded anonymously. They become the “what do owners actually believe” dataset.

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001723128-24-000014 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2022-12-31 · accession 0001723128-25-000012 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K · period ending 2023-12-31 · accession 0001723128-26-000011 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2021-12-31 · accession 0001723128-24-000014 (NetIncomeLoss)
  5. 10-K · period ending 2023-12-31 · accession 0001723128-26-000011 (NetIncomeLoss)
  6. 10-K · period ending 2021-12-31 · accession 0001723128-24-000014 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2022-12-31 · accession 0001723128-25-000012 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2023-12-31 · accession 0001723128-26-000011 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2021-12-31 · accession 0001723128-24-000014 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K · period ending 2022-12-31 · accession 0001723128-25-000012 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2023-12-31 · accession 0001723128-26-000011 (PaymentsToAcquirePropertyPlantAndEquipment)
  12. 10-K · period ending 2021-12-31 · accession 0001723128-23-000009 (LongTermDebtNoncurrent)
  13. 10-K · period ending 2022-12-31 · accession 0001723128-24-000014 (LongTermDebtNoncurrent)
  14. 10-K · period ending 2023-12-31 · accession 0001723128-25-000012 (LongTermDebtNoncurrent)
  15. 10-K · period ending 2024-12-31 · accession 0001723128-26-000011 (LongTermDebtNoncurrent)
  16. 10-K · period ending 2021-12-31 · accession 0001723128-24-000014 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2022-12-31 · accession 0001723128-25-000012 (CashAndCashEquivalentsAtCarryingValue)
  18. 10-K · period ending 2023-12-31 · accession 0001723128-26-000011 (CashAndCashEquivalentsAtCarryingValue)